Cyclophilins in Atherosclerosis: A new therapeutic target?

Current Pharmaceutical Design

Volumn 19, Issue 33, 2013, Pages 5904-5908

  Bukrinsky, Michael ^a   Orekhov, Alexander ^b   Ditiatkovski, Michael ^c   Sviridov, Dmitri ^c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Institute for Atherosclerosis Research   (Russian Federation)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

CD147; Chemotaxis; Extracellular cyclophilins; Inflammation; Leukocytes; Monocytes

Indexed keywords

CD147 ANTIGEN; CHEMOATTRACTANT; CHEMOTAXIS AFFECTING AGENT; COLONY STIMULATING FACTOR 1; CYCLOPHILIN A; CYCLOPHILIN B; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; PEPTIDYLPROLYL ISOMERASE; REACTIVE OXYGEN METABOLITE; STROMELYSIN;

ATHEROSCLEROSIS; CELL PERMEABILIZATION; DETOXIFICATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROBLAST; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MONOCYTE; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD147; ATHEROSCLEROSIS; CHEMOTACTIC FACTORS; CYCLOPHILINS; CYCLOSPORINS; ENDOTHELIUM, VASCULAR; HUMANS; MATRIX METALLOPROTEINASES; MOLECULAR TARGETED THERAPY;

EID: 84884244057     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319330009     Document Type: Review

References (80)

1. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-15.
2. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008; 28: 1897-908.
3. Drechsler M, Megens RT, van ZM, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837-45.
4. Baetta R, Corsini A. Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis 2010; 210: 1-13.
5. Amasyali B, Kose S, Kursaklioglu H, Barcin C, Kilic A. Monocyte chemoattractant protein-1 in acute coronary syndromes: complex vicious interaction. Int J Cardiol 2009; 136: 356-7.
6. Kamari Y, Werman-Venkert R, Shaish A, et al. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 2007; 195: 31-38.
7. Liao YH, Xia N, Zhou SF, et al. Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol 2012; 59: 420-9.
8. Ditiatkovski M, Toh BH, Bobik A. GM-CSF deficiency reduces macrophage PPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 2337-44.
9. Montecucco F, Steffens S, Burger F, et al. Tumor necrosis factoralpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) upregulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. Cell Signal 2008; 20: 557-68.
10. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-81.
11. Gleissner CA, von HP, Ley K. Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 2008; 28: 1920-7.
12. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2292-301.
13. Sheikine YA, Hansson GK. Chemokines as potential therapeutic targets in atherosclerosis. Curr Drug Targets 2006; 7: 13-27.
14. Koenen RR, Weber C (2011) Chemokines: established and novel targets in atherosclerosis. EMBO Mol Med 3: 713-25.
15. Bukrinsky MI. Cyclophilins: unexpected messengers in intercellular communications. Trends Immunol 2002; 23: 323-5.
16. Wang P, Heitman J. The cyclophilins. Genome Biol 2005; 6: 226.
17. Yurchenko V, Zybarth G, O'Connor M, et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 2002; 277: 22959-65.
18. Arora K, Gwinn WM, Bower MA, et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005; 175: 517-22.
19. Gwinn WM, Damsker J, Falahati R, et al. Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. J Immunol 2006; 177: 4870-9.
20. Damsker JM, Bukrinsky MI, Constant SL. Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol 2007; 82: 613-8.
21. Sherry B, Yarlett N, Strupp A, Cerami A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci USA 1992; 89: 3511-5.
22. Xu Q, Leiva MC, Fischkoff SA, Handschumacher RE, Lyttle CR. Leukocyte chemotactic activity of cyclophilin. J Biol Chem 1992; 267: 11968-71.
23. Khromykh LM, Kulikova NL, Anfalova TV, et al. Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol 2007; 249: 46-53.
24. Yurchenko V, O'Connor M, Dai WW, et al. CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun 2001; 288: 786-8.
25. Kim K, Kim H, Jeong K, et al. Release of overexpressed CypB activates ERK signaling through CD147 binding for hepatoma cell resistance to oxidative stress. Apoptosis 2012; 17: 784-96.
26. Bauer K, Kretzschmar AK, Cvijic H, et al. Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells. Oncogene 2009; 28: 2784-95.
27. Bahmed K, Henry C, Holliday M, et al. Extracellular cyclophilin-A stimulates ERK1/2 phosphorylation in a cell-dependent manner but broadly stimulates nuclear factor kappa B. Cancer Cell Int 2012; 12: 19.
28. Price ER, Zydowsky LD, Jin MJ, Baker CH, McKeon FD, Walsh CT. Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. Proc Natl Acad Sci USA 1991; 88: 1903-7.
29. Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res 2006; 98: 811-7.
30. Yuan W, Ge H, He B. Pro-inflammatory activities induced by CyPA-EMMPRIN interaction in monocytes. Atherosclerosis 2010; 213: 415-21.
31. Heine SJ, Olive D, Gao JL, Murphy PM, Bukrinsky MI, Constant SL. Cyclophilin A cooperates with MIP-2 to augment neutrophil migration. J Inflamm Res 2011; 4: 93-104.
32. Allain F, Vanpouille C, Carpentier M, Slomianny MC, Durieux S, Spik G. Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc Natl Acad Sci USA 2002; 99: 2714-9.
33. Pakula R, Melchior A, Denys A, Vanpouille C, Mazurier J, Allain F. Syndecan-1/CD147 association is essential for cyclophilin Binduced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis. Glycobiology 2007; 17: 492-503.
34. Damsker JM, Okwumabua I, Pushkarsky T, Arora K, Bukrinsky MI, Constant SL. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. Immunology 2009; 126: 55-62.
35. Joseph J, Knobler RL, Lublin FD, Burns FR. Regulation of the expression of intercellular adhesion molecule-1 (ICAM-1) and the putative adhesion molecule Basigin on murine cerebral endothelial cells by MHV-4 (JHM). Adv Exp Med Biol 1993; 342: 389-91.
36. Radons J, Multhoff G. Immunostimulatory functions of membranebound and exported heat shock protein 70. Exerc Immunol Rev 2005; 11: 17-33.
37. Hreggvidsdottir HS, Ostberg T, Wahamaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009; 86: 655-62.
38. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165: 2950-4.
39. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
40. Lee J, Kim SS. Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res 2010; 29: 97.
41. Yurchenko V, Constant S, Eisenmesser E, Bukrinsky M. Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics. Clin Exp Immunol 2010; 160: 305-17.
42. Jin ZG, Melaragno MG, Liao DF, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res 2000; 87: 789-96.
43. Liao DF, Jin ZG, Baas AS, et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000; 275: 189-96.
44. Nigro P, Satoh K, O'Dell MR, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein Edeficient mice. J Exp Med 2011; 208: 53-66.
45. Payeli SK, Schiene-Fischer C, Steffel J, et al. Cyclophilin A differentially activates monocytes and endothelial cells: role of purity, activity, and endotoxin contamination in commercial preparations. Atherosclerosis 2008; 197: 564-71.
46. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC. Cyclophilin A Is a Proinflammatory Cytokine that Activates Endothelial Cells. Arterioscler Thromb Vasc Biol 2004; 24: 1186-91.
47. Seizer P, Schonberger T, Schott M, et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis 2010; 209: 51-7.
48. Kim JY, Kim WJ, Kim H, Suk K, Lee WH. The Stimulation of CD147 Induces MMP-9 Expression through ERK and NF-kappaB in Macrophages: Implication for Atherosclerosis. Immune Netw 2009; 9: 90-7.
49. Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal 2010; 12: 675-82.
50. Mikol V, Kallen J, Pflugl G, Walkinshaw MD. X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. J Mol Biol 1993; 234: 1119-30.
51. Liu J, Farmer JDJ, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-15.
52. Friedman J, Weissman I. Two cytoplasmic candidates for immunophilin action are revealed by affinity for a new cyclophilin: one in the presence and one in the absence of Cs A. Cell 1991; 66: 799-806.
53. Prashar Y, Khanna A, Sehajpal P, Sharma VK, Suthanthiran M. Stimulation of transforming growth factor-beta 1 transcription by cyclosporine. FEBS Lett 1995; 358: 109-12.
54. Jin S, Mathis AS, Rosenblatt J, et al. Insights into cyclosporine Ainduced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation. Transplantation 2004; 77: 497-504.
55. Roselaar SE, Schonfeld G, Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cellmediated immunity. J Clin Invest 1995; 96: 1389-94.
56. Drew AF, Tipping PG. Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis 1995; 116: 181-9.
57. Emeson EE, Shen ML. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am J Pathol 1993; 142: 1906-15.
58. Moghadasian MH. Dietary phytosterols reduce cyclosporineinduced hypercholesterolemia in apolipoprotein E-knockout mice. Transplantation 2006; 81: 207-13.
59. Le Goff W, Peng DQ, Settle M, Brubaker G, Morton RE, Smith JD. Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 2155-61.
60. Zheng XL, Wong NC. Cyclosporin A inhibits apolipoprotein AI gene expression. J Mol Endocrinol 2006; 37: 367-73.
61. Kockx M, Guo DL, Traini M, et al. Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway. J Biol Chem 2009; 284: 24144-54.
62. Lungu AO, Jin ZG, Yamawaki H, Tanimoto T, Wong C, Berk BC. Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. J Biol Chem 2004; 279: 48794-800.
63. Lu H, Enosawa S, Ohmi K, Suzuki S. The proliferative response of p53 knock-out mouse-derived vascular smooth muscle cell line, P53LMAC01, to PDGF, when compared with human aortic smooth muscle cells. Transpl Immunol 2001; 8: 253-7.
64. Kockx M, Jessup W, Kritharides L. Cyclosporin A and atherosclerosis--cellular pathways in atherogenesis. Pharmacol Ther 2010; 128: 106-18.
65. Elbaz B, Valitsky M, Davidov G, Rahamimoff H. Cyclophilin A is involved in functional expression of the Na(+)-Ca(2+) exchanger NCX1. Biochemistry 2010; 49: 7634-42.
66. Song F, Zhang X, Ren XB, et al. Cyclophilin A (CyPA) induces chemotaxis independent of its peptidylprolyl Cis-trans isomerase activity: Direct binding between CyPA and the ectodomain of CD147. J Biol Chem 2011.
67. Malesevic M, Kuhling J, Erdmann F, et al. A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins. Angew Chem Int Ed Engl 2010; 49: 213-5.
68. Balsley MA, Malesevic M, Stemmy EJ, et al. A cell-impermeable cyclosporine a derivative reduces pathology in a mouse model of allergic lung inflammation. J Immunol 2010; 185: 7663-70.
69. Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 2003; 54: 371-89.
70. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61: 2276-81.
71. Li R, Huang L, Guo H, Toole BP. Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J Cell Physiol 2001; 186: 371-9.
72. Sameshima T, Nabeshima K, Toole BP, et al. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett 2000; 157: 177-84.
73. Zhou J, Zhu P, Jiang JL, et al. Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1. BMC Cell Biol 2005; 6: 25.
74. Zhu P, Lu N, Shi ZG, et al. CD147 overexpression on synoviocytes in rheumatoid arthritis enhances matrix metalloproteinase production and invasiveness of synoviocytes. Arthritis Res Ther 2006; 8: R44.
75. Kim H, Kim WJ, Jeon ST, et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol 2005; 116: 217-24.
76. Yang Y, Lu N, Zhou J, Chen ZN, Zhu P. Cyclophilin A upregulates MMP-9 expression and adhesion of monocytes/ macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 1299-310.
77. Back M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010; 52: 410-28.
78. Lee WH, Kim SH, Lee Y, et al. Tumor necrosis factor receptor superfamily 14 is involved in atherogenesis by inducing proinflammatory cytokines and matrix metalloproteinases. Arterioscler Thromb Vasc Biol 2001; 21: 2004-10.
79. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 2640-7.
80. Schmidt R, Bultmann A, Ungerer M, et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 2006; 113: 834-41.